One In, One Out: Mirum Seeks New EU Indication For Maralixibat, Withdraws Another
Kyowa Kirin And Sanofi Want CHMP To Re-Examine Earlier Opinion About Their Products
Sponsors of three drugs have withdrawn their EU marketing authorization applications in the middle of the assessment process, including one for a bladder cancer therapy that was recently turned down in the US.
You may also be interested in...
Regulators have approved Mirum's IBAT inhibitor as the first medication for a genetic disorder which affects up to 2,500 children in the US.
A number of new medicines are moving closer to the EU market after the European Medicines Agency recommended in favor of their approval.
A complete response letter from the FDA has dashed Sesen Bio’s hopes of being first with a therapy for treating BCG-unresponsive non-muscle invasive bladder cancer. Its CEO says the FDA’s move may reflect heightened ‘pressure’ regulator is under.